Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Odyssey Therapeutics, Inc. - Common Stock
(NQ:
ODTX
)
18.93
+0.05 (+0.26%)
Delayed Quote
Updated: 11:12 AM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Odyssey Therapeutics, Inc. - Common Stock
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 04, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
October 20, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
October 12, 2026
Topline induction results expected in the second half of 2027
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
October 06, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
September 16, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
June 17, 2026
From
Odyssey Therapeutics Inc
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
